Nucleoside News and Research

RSS

Pharmasset reports net loss of $16.1 million for fiscal second-quarter 2010

Pharmasset, Inc., a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended March 31, 2010.

6 May 2010

Clinical development of RG7128 is on track: Pharmasset

Pharmasset, Inc., in response to certain inaccuracies in an article published by PharmaWire on May 3, 2010 about its development program for treatment of hepatitis C virus in collaboration with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd, stated today that the development of RG7128 is on track, and that no safety or other concerns have delayed the program.

4 May 2010

Gilead announces bioequivalence of Truvada in combination with Tibotec Pharmaceuticals' TMC278 NNRTI

Gilead Sciences, Inc. announced today it has obtained data supporting bioequivalence of a formulation of the fixed-dose combination of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride, 25 mg).

29 Apr 2010

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.

28 Apr 2010

Updates on development of Truvada and TMC278

Gilead Sciences, Inc. provided an update today on the development of the fixed-dose combination of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride, 25 mg).

21 Apr 2010

Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus

Anadys Pharmaceuticals, Inc. announced today that 72% of hepatitis C patients receiving ANA598 400 mg twice daily (bid) plus standard of care achieved undetectable levels of virus at week eight in an ongoing Phase II study, compared to 38% of patients receiving placebo plus SOC.

19 Apr 2010

Investment report on Idenix Pharmaceuticals

StockPreacher.com announces an investment report featuring Idenix Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

16 Apr 2010

Investment report on Anadys Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Anadys Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

16 Apr 2010

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 14-day, phase IIa clinical trial evaluating IDX184, a novel liver-targeted nucleotide prodrug of 2'-methyl guanosine monophosphate, in HCV-infected patients.

15 Apr 2010

TriLink partners with Cedarlane to enhance distribution of its products in Canada

TriLink BioTechnologies, has entered into an agreement with Cedarlane Corporation, a Canadian based research biotechnology company, for the sale and distribution of its modified nucleoside triphosphates, custom chemistry and oligonucleotide products.

9 Apr 2010

Phase 1 SAD study of PSI-938 for HCV initiated

Pharmasset, Inc. announced today that dosing has initiated in a phase 1, single ascending dose study in healthy volunteers with PSI-938, a third generation purine nucleotide analog polymerase inhibitor of hepatitis C virus. Pharmasset recently filed an Investigational New Drug Application with the Food and Drug Administration.

8 Apr 2010

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

Vertex Pharmaceuticals Incorporated today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010.

17 Mar 2010

Drinking coffee may lower risk of hospitalization for heart rhythm disturbances

Coffee drinkers may be less likely to be hospitalized for heart rhythm disturbances, according to a new study by the Kaiser Permanente Division of Research in Oakland, Calif. The researchers, who note the findings may be surprising because patients frequently report palpitations after drinking coffee, are presenting the study at the American Heart Association's 50th Annual Conference on Cardiovascular Disease Epidemiology and Prevention in San Francisco on March 5, 2010.

3 Mar 2010

Abbott and Enanta advance treatment for Hepatitis C

Abbott and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C (HCV) collaboration into Phase 2 clinical trials.

2 Mar 2010

Recent releases in Global Health

The Infectious Diseases Center for Global Health Policy's "Science Speaks" blog examines U.S. Global AIDS Coordinator Eric Goosby's recent address to the Conference on Retroviruses and Opportunistic Infections (CROI) where he reemphasized the Obama administration's commitment to "'maintaining, extending and increasing' the U.S. response to global AIDS." Goosby reflected on the lessons drawn from PEPFAR to date and presented components of the 5-year PEPFAR strategy, the blog notes.

20 Feb 2010

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir (r) (800/100 mg) once-daily arm achieved undetectable viral loads (<50 copies/mL) compared with 71 percent of patients in the PREZISTA/r (600/100 mg) twice-daily arm. The study met its primary objective of non-inferiority. These data from the Phase 3b ODIN study were presented today at CROI 2010, the 17th Conference on Retroviruses and Opportunistic Infections, in San Francisco.

18 Feb 2010

Study: sdNVP can lead to HIV treatment failure in women receiving drug to prevent infant infection

A new international study reported in PLoS Medicine confirms that a single dose of nevirapine (sdNVP) can lead to HIV treatment failure in women who receive the drug to prevent transmission of the AIDS virus to their infants. However, the increased risk of failure could only be detected in women who began full HIV treatment within about a year after receiving sdNVP.

16 Feb 2010

$Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia$

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of perifosine (KRX-0401) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of the Journal of Clinical Cancer Research.

30 Jan 2010

Positive Phase 2 trial results of Keryx Biopharmaceuticals' KRX-0401 announced

Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.

29 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010